SL22P CAR-T cells
/ SenlangBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 19, 2020
Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Clinical • New P1 trial • Cervical Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcoma • Solid Tumor
1 to 1
Of
1
Go to page
1